Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Siddique Abbasi"'
Autor:
Winnie Sohn, Jan Wahlstrom, Marintan Spring, Hanze Zhang, Siddique Abbasi, Stephen Flach, Sandeep Dutta, Priyanka Kulkarni, Ashit Trivedi, Edward Lee, Pegah Jafarinasabian
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with h
Autor:
Sandeep Dutta, Bianca Terminello, Pegah Jafarinasabian, Winnie Sohn, Siddique Abbasi, Hanze Zhang, Edward Lee, Ashit Trivedi, Stephen Flach
Publikováno v:
Clinical Pharmacology in Drug Development. 11:129-133
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure (HF) with reduced ejection fraction. OM is administered as a 25-, 37.5-, or 50-mg modified-release formulation in patients with HF. Proton p
Autor:
Stephen Flach, Ashit Trivedi, Siddique Abbasi, Sandeep Dutta, Fady I. Malik, Hanze Zhang, Pegah Jafarinasabian, Edward Lee
Publikováno v:
Clinical Pharmacology in Drug Development. 11:185-193
Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The effect of CYP3A4 and CYP2D6 inhibition on OM pharmacokinetics and the potential for OM to induce CYP3A4 was assessed in 2 studies. Study 1
Autor:
Hanze Zhang, Pegah Jafarinasabian, Shauna Hutton, Siddique Abbasi, Mia Mackowski, Rajneet K. Oberoi, Stephen Flach, Edward Lee, Sandeep Dutta, Ashit Trivedi
Publikováno v:
Clinical Pharmacology in Drug Development. 10:1442-1451
Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. OM is primarily eliminated via metabolism mediated by multiple cytochrome P450 enzymes. This
Autor:
Hanze Zhang, Edward Lee, Marintan Spring, Siddique Abbasi, Pegah Jafarinasabian, Ashit Trivedi, Rajneet K. Oberoi, Stephen Flach, Sandeep Dutta
Publikováno v:
Clinical Drug Investigation. 41:647-652
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure with reduced ejection fraction. The objective of this study was to evaluate the potential for OM to affect the pharmacokinetics of metformin
Autor:
Edward Lee, Sandeep Dutta, Siddique Abbasi, Mia Mackowski, Makoto Aoki, Ashit Trivedi, Fady I. Malik, Shauna Hutton
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 46(6)
Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The pharmacokinetics of single and multiple doses of OM were investigated in healthy Japanese subjects in two clinical studies. Study 1 (n = 3
Autor:
Edward Lee, Sandeep Dutta, Winnie Sohn, Cheng-Pang Hsu, Stephen Flach, Pegah Jafarinasabian, Siddique Abbasi, Hanze Zhang, Shauna Hutton, Ashit Trivedi
Publikováno v:
Clinical pharmacology in drug development. 11(3)
Omecamtiv mecarbil (OM), a novel cardiac myosin activator, is being evaluated for the treatment of heart failure with reduced ejection fraction. In vitro studies demonstrate OM as a substrate and inhibitor of P-glycoprotein (P-gp), which can result i
Autor:
Borje Darpo, Cheng-Pang Hsu, Sandeep Dutta, Hongqi Xue, Bianca Terminello, Stephen Flach, Ashley Brooks, Siddique Abbasi, Samuel Israel, Edward Lee, Pegah Jafarinasabian, Hanze Zhang, Ashit Trivedi
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(1)
AIMS Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure. This study aimed to evaluate the effect of therapeutic concentrations of OM on electrocardiogram (ECG) parameters and e
Autor:
Rajneet K. Oberoi, Bianca Terminello, Ashit Trivedi, Stephen Flach, Pegah Jafarinasabian, Edward Lee, Siddique Abbasi, Mary Ann Simiens, Mia Mackowski, Hanze Zhang, Sandeep Dutta
Publikováno v:
Biopharmaceuticsdrug dispositionREFERENCES. 42(7)
Omecamtiv mecarbil (OM) is a cardiac myosin activator in clinical development for the treatment of heart failure. The effect of food on the pharmacokinetics (PK) of 25, 37.5, and 50 mg strength modified release (MR) tablets and the bioequivalence of
Autor:
Hanze Zhang, Rajneet K. Oberoi, Stephen Flach, Siddique Abbasi, Sandeep Dutta, Ashit Trivedi, Pegah Jafarinasabian, Edward Lee
Publikováno v:
Clinical Pharmacokinetics
Background and Objective Omecamtiv mecarbil is a novel selective cardiac myosin activator (myotrope) under investigation for the treatment of heart failure with reduced ejection fraction. The objective of this clinical study was to estimate the effec